Understanding and overcoming resistance to PARP inhibitors in cancer therapy

• Published in: Nature reviews. Clinical oncology Vol. 18; no. 12; pp. 773 - 791
• Main Authors: Dias, Mariana Paes, Moser, Sarah C., Ganesan, Shridar, Jonkers, Jos
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.12.2021; Nature Publishing Group
• Subjects: 631/337/1427/2566; 631/67/1059/2326; 692/4028/67/1059/2326; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; BRCA1 protein; Cancer; Cancer therapies; Care and treatment; Clinical trials; Clinical Trials as Topic; DNA repair; Drug resistance; Drug Resistance, Neoplasm - drug effects; Drug Therapy; Enzyme inhibitors; Genetic aspects; Genomic instability; Genomic Instability - drug effects; Health aspects; Homologous recombination; Humans; Medicine; Medicine & Public Health; Neoplasms - drug therapy; Neoplasms - genetics; Oncology; Patient outcomes; Patients; Poly(ADP-ribose); Poly(ADP-ribose) polymerase; Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use; Prevention; Review Article; Ribose; Targeted cancer therapy; Tumors; Netherlands

Developing novel targeted anticancer therapies is a major goal of current research. The use of poly(ADP-ribose) polymerase (PARP) inhibitors in patients with homologous recombination-deficient tumours provides one of the best examples of a targeted therapy that has been successfully translated into...